Development of a quantitative diagnostic method of estrogen receptor expression levels by immunohistochemistry using organic fluorescent material-assembled nanoparticles

Biochemical and Biophysical Research Communications

Volumn 426, Issue 3, 2012, Pages 409-414

  Gonda, Kohsuke ^a   Miyashita, Minoru ^a   Watanabe, Mika ^b   Takahashi, Yayoi ^b   Goda, Hideki ^c   Okada, Hisatake ^c   Nakano, Yasushi ^c   Tada, Hiroshi ^a   Amari, Masakazu ^a   Ohuchi, Noriaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c Konica Minolta Technology Center Inc   (Japan)

Author keywords

Cancer; Diagnosis; Estrogen receptor; Immunohistochemistry; Nanoparticle; Quantitative sensitivity

Indexed keywords

DIAMINOBENZIDINE; ESTROGEN RECEPTOR; HORSERADISH PEROXIDASE; MACROGOL; NANOPARTICLE; ORGANIC FLUORESCENT MATERIAL ASSEMBLED NANOPARTICLE; QUANTUM DOT; TETRAMETHYLRHODAMINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOFLUORESCENCE; BREAST CANCER; CANCER DIAGNOSIS; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG TARGETING; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; REACTION TIME; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; TISSUE SECTION;

BREAST NEOPLASMS; FEMALE; FLUORESCENCE; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; NANOPARTICLES; RECEPTORS, ESTROGEN; RHODAMINES; STAINING AND LABELING; STREPTAVIDIN;

ARMORACIA RUSTICANA;

EID: 84866888392     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.105     Document Type: Article

References (12)

1. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology 2008, 21:S8-S15.
2. Moriya T., Kanomata N., Kozuka Y., Hirakawa H., Kimijima I., Kimura M., Watanabe M., Sasano H., Ishida T., Ohuchi N., Kurebayashi J., Sonoo H. Molecular morphological approach to the pathological study of development and advancement of human breast cancer. Medical Molecular Morphology 2010, 43:67-73.
3. Ven S.V.D., Smit V.T.H.B.M., Dekker T.J.A., Nortier J.W.R., Kroep J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treatment Reviews 2011, 37:422-430.
4. Leong A.S.-Y., Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 2011, 78:99-114.
5. Thomas C., Gustafsson J.-Å. The different roles of ER subtypes in cancer biology and therapy. Nature Reviews Cancer 2011, 11:597-608.
6. Lidke D.S., Nagy P., Heintzmann R., Arndt-Jovin D.J., Post J.N., Grecco H.E., Jares-Erijman E.A., Jovin T.M. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nature Biotechnology 2004, 22:198-203.
7. Blaaderen A.V., Vrij A. Synthesis and characterization of colloidal dispersions of fluorescent, monodisperse silica spheres. Langmuir 1992, 8:2921-2931.
8. Verhaegh N.A.M., Blaaderen A.v. Dispersions of rhodamine-labeled silica spheres: synthesis, characterization, and fluorescence confocal scanning laser microscopy. Langmuir 1994, 10:1427-1438.
9. Gonda K., Watanabe T.M., Ohuchi N., Higuchi H. In vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots. Journal of Biological Chemistry 2009, 285:2750-2757.
10. Hamada Y., Gonda K., Takeda M., Sato A., Watanabe M., Yambe T., Satomi S., Ohuchi N. In vivo imaging of molecular distribution of the VEGF receptor during angiogenesis in a mouse model of ischemia. Blood 2011, 118:e93-e100.
11. Stingl J., Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nature Reviews Cancer 2007, 7:791-799.
12. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nature Reviews Cancer 2012, 12:323-334.